Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe.

  • 1 April 2000
    • Vol. 355  (9210) , 1158-9
Abstract
We compared survival from HIV-1 seroconversion before and during the periods of highly-active antiretroviral therapy (HAART). Survival expectations were substantially better for HIV-1-infected individuals in 1997-98 (HAART period) compared with those in 1986-96 (pre-HAART period). Estimated survival 10 years from seroconversion was also substantially better in the later period.

This publication has 0 references indexed in Scilit: